A detailed history of Ameriprise Financial Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 4,281,482 shares of BMRN stock, worth $268 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
4,281,482
Previous 4,701,326 8.93%
Holding current value
$268 Million
Previous $387 Million 22.25%
% of portfolio
0.08%
Previous 0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $29 Million - $39.4 Million
-419,844 Reduced 8.93%
4,281,482 $301 Million
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $52.3 Million - $64.8 Million
-702,219 Reduced 13.0%
4,701,326 $387 Million
Q1 2024

May 15, 2024

SELL
$83.81 - $99.0 $1.33 Million - $1.57 Million
-15,821 Reduced 0.29%
5,403,545 $472 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $19.5 Million - $25.2 Million
255,417 Added 4.95%
5,419,366 $523 Million
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $23.4 Million - $26 Million
275,436 Added 5.63%
5,163,949 $457 Million
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $4.32 Million - $5 Million
-49,833 Reduced 1.01%
4,888,513 $424 Million
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $25.4 Million - $34 Million
289,718 Added 6.23%
4,938,346 $480 Million
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $84.7 Million - $114 Million
-1,046,606 Reduced 18.38%
4,648,628 $481 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $9.89 Million - $11.7 Million
-120,343 Reduced 2.07%
5,695,234 $483 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $34 Million - $41.3 Million
475,127 Added 8.9%
5,815,577 $482 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $90 Million - $112 Million
-1,211,211 Reduced 18.49%
5,340,450 $412 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $19.9 Million - $25.4 Million
-277,515 Reduced 4.06%
6,551,661 $579 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $20.9 Million - $23.8 Million
278,927 Added 4.26%
6,829,176 $528 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $23.9 Million - $26.9 Million
316,914 Added 5.08%
6,550,249 $547 Million
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $140 Million - $170 Million
1,873,040 Added 42.96%
6,233,335 $471 Million
Q4 2020

Feb 12, 2021

BUY
$72.61 - $90.2 $98.3 Million - $122 Million
1,354,135 Added 45.05%
4,360,295 $382 Million
Q3 2020

Nov 16, 2020

SELL
$71.87 - $131.03 $9.17 Million - $16.7 Million
-127,540 Reduced 4.07%
3,006,160 $229 Million
Q2 2020

Aug 14, 2020

BUY
$79.55 - $124.22 $10.8 Million - $16.8 Million
135,564 Added 4.52%
3,133,700 $387 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $14.2 Million - $19.2 Million
-198,723 Reduced 6.22%
2,998,136 $253 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $19.6 Million - $26.4 Million
305,237 Added 10.56%
3,196,859 $270 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $217,634 - $274,820
3,229 Added 0.11%
2,891,622 $195 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $18.9 Million - $22.1 Million
235,219 Added 8.87%
2,888,393 $247 Million
Q1 2019

May 15, 2019

SELL
$84.2 - $98.62 $677,473 - $793,496
-8,046 Reduced 0.3%
2,653,174 $236 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $5.32 Million - $7.04 Million
-66,384 Reduced 2.43%
2,661,220 $227 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $27.5 Million - $31 Million
293,137 Added 12.04%
2,727,604 $266 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $121 Million - $158 Million
1,597,750 Added 190.95%
2,434,467 $229 Million
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $16.7 Million - $20 Million
-215,427 Reduced 20.48%
836,717 $67.8 Million
Q4 2017

Feb 12, 2018

BUY
$80.76 - $95.13 $6.57 Million - $7.74 Million
81,380 Added 8.38%
1,052,144 $93.8 Million
Q3 2017

Nov 07, 2017

BUY
$80.6 - $94.95 $78.2 Million - $92.2 Million
970,764
970,764 $90.3 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.6B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.